Strnad emphasizes the promise offered by RNA therapeutics in liver disease and what potential fazirsiran may hold for AATD liver disease in a broad spectrum of patients.
Pavel Strnad, MD
Advertisement
Pavel Strnad, MD, is a full professor and leading physician at the University Hospital Aachen in Germany.
Articles by Pavel Strnad, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5